Chinese BCI startup Gestala raises $21.6M for non-invasive ultrasound brain tech
Back to Home
tech

Chinese BCI startup Gestala raises $21.6M for non-invasive ultrasound brain tech

March 12, 202619 views2 min read

Chinese BCI startup Gestala has raised $21.6 million in a funding round that marks the largest early-stage brain-computer interface investment in China. The company is developing non-invasive ultrasound brain stimulation technology.

In a significant development for the brain-computer interface (BCI) industry, Chinese startup Gestala has raised $21.6 million in a funding round that marks the largest early-stage BCI investment in China to date. The company, which was founded just two months prior to the raise, has drawn strong interest from investors, with the funding round being heavily oversubscribed.

Non-Invasive Ultrasound Technology

Gestala's approach to BCI differs from traditional methods that often rely on invasive implants. Instead, the company is developing non-invasive brain stimulation technology using ultrasound. This method could significantly reduce the risks associated with surgical procedures, while still offering the potential to enhance cognitive functions or treat neurological disorders. The technology aims to modulate neural activity through focused ultrasound waves, enabling new forms of human-computer interaction.

Founder’s Vision and Past Success

The funding comes on the heels of founder Phoenix Peng’s previous success with NeuroXess, his first BCI venture. NeuroXess focuses on implantable systems designed to restore communication and motor function for patients with severe neurological conditions. With this new investment, Peng is expanding his focus into non-invasive solutions, signaling a shift toward broader accessibility and safer applications in the BCI space. Analysts believe this move positions Gestala at the forefront of a growing trend in the global BCI market, where safety and ease of use are becoming key differentiators.

Future Prospects

With the capital secured, Gestala is expected to accelerate research and development efforts, potentially bringing its technology closer to clinical trials and real-world applications. The company’s non-invasive approach could open doors for treating a wide range of conditions, from paralysis to depression, while also laying the groundwork for consumer-facing brain interfaces in the future.

The investment underscores China’s growing influence in the global BCI landscape, as the country continues to invest heavily in emerging technologies that promise to reshape how humans interact with machines.

Source: TNW Neural

Related Articles